Results 261 to 270 of about 318,537 (297)

Targeting Microglial CD49a Inhibits Neuroinflammation and Demonstrates Therapeutic Potential for Parkinson's Disease

open access: yesAdvanced Science, EarlyView.
This study shows that integrin receptor CD49a (Itga1 gene) is significantly upregulated in hyperactivated microglia and microglia‐specific knockdown of Itga1 rescues neuroinflammation and neurodegeneration in a chronic Parkinson's disease (PD) model by targeting PGAM5‐mediated mitochondrial dysfunction and NLRP3 activation. Targeted inhibition of CD49a
Huanpeng Lu   +6 more
wiley   +1 more source

miR-126-5p protects from URSA via inhibiting Caspase-1-dependent pyroptosis of trophoblast cells. [PDF]

open access: yesCell Mol Life Sci
Zhu X   +13 more
europepmc   +1 more source

PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma

open access: yesAdvanced Science, EarlyView.
Integrated scRNA‐seq, scTCR‐seq analysis, and functional assays identify PRDM1+ malignant epithelial cells with hyper lipid peroxidation characteristics that demonstrate reduced responsiveness to the nICRT treatment. Principal factor PRDM1 activates cysteine metabolism genes to modulate lipid peroxidation (an intrinsic cellular pathway related to ...
Dijian Shen   +12 more
wiley   +1 more source

Magnesium Structure‐Function Integration Platform for Spatiotemporal Multi‐Modality Therapy: Combining Hormonotherapy and Immunotherapy in Prostate Cancer

open access: yesAdvanced Science, EarlyView.
The schematic illustration of the MHSCG platform for spatiotemporal responsive GRb1 release to induce androgen deprivation therapy (ADT) and immunogenic cell death (ICD) multimodal therapy in prostate cancer. Abstract Metal‐based immunotherapy represents a promising strategy for enhancing antitumor efficacy; however, its clinical application is limited
Rui Zan   +13 more
wiley   +1 more source

Stimuli‐Responsive Supramolecular Biomaterials for Cancer Theranostics

open access: yesAdvanced Science, EarlyView.
The ultimate goal of cancer theranostics is to get imaging agents and therapeutic cargo to tumor sites when and where they are required. “Smart” systems should be developed. This review discusses the characteristics of physiological stimuli, types and action modes of external stimuli, construction approaches and working principles, as well as ...
Wenting Hu   +4 more
wiley   +1 more source

The bone phenotype associated with cherubism is independent of Caspase-1-dependent inflammasome activation in the mouse. [PDF]

open access: yesPLoS One
Rabhi BV   +6 more
europepmc   +1 more source

DNMT2‐m5C‐ACLY Axis Promotes Lenvatinib Resistance in Hepatocellular Carcinoma Through Histone Acetylation‐Mediated Notch Pathway

open access: yesAdvanced Science, EarlyView.
Lenvatinib resistance poses a major challenge in advanced hepatocellular carcinoma (HCC). This study reveals that DNMT2 upregulation is a key driver, which stabilizes ACLY mRNA via m5C modification and activates the Notch signaling pathway. Crucially, combining ACLY inhibitors with lenvatinib overcomes resistance and suppresses tumors, offering a ...
Shiguang Yang   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy